

Position Paper

FEBRUARY 2024



1. Introduction

Brand Plans are often inefficient and of little use due to insufficient brand teams' involvement, lack of market insights and of coordination across pharma companies' departments

• Smart Pharma consultants have helped 35 pharma companies develop brand plans on more than 80 products belonging to 18 different therapeutic areas:

1.	Allergy	7.	Immunology	13.	. Oncology
2.	Cardiology	8.	Infectiology / Virology	14.	. Pulmonology
3.	Dermatology	9.	Metabolism / Diabetes	15	. Psychiatry
4.	Gastroenterology	10.	Nephrology	16	. Rare diseases (various)
5.	Gynecology	11.	Neurology	17	. Rheumatology
6.	Hematology	12.	Ophthalmology	18	. Urology

 From this experience, we have identified several common pitfalls that should be avoided to craft brand plans likely to optimize brand performance

"At affiliate level, the Brand Planning process is often viewed as a window-dressing exercise"



1. Introduction

For each of these five pitfalls, we propose practical and easy-to-implement solutions so that pharma companies can transform useless brand plans into high-performance ones

Pitfall #1

Describing and not analyzing the market situation

Pitfall #2

Carrying out a sub-optimal SWOT analysis

Pitfall #3

Crafting an inconsistent strategy

Pitfall #4

Selecting tactics which do not support the strategy

Pitfall #5

Not integrating monitoring indicators

"The purpose of Brand Plans is to allocate the right resources to reach the performance objective set, in an effective and efficient way"




Market situation is too often superficially analyzed and therefore poorly understood, preventing a proper identification of market opportunities and threats

Pitfall #1

Describing and not analyzing the market situation

What do we observe?



- The situation analysis section is most often just a description of the market facts with no or poor analyses
- Despite a large quantity of available data, the knowledge and the understanding of key market stakeholders are too often partial and not accurate
- The main reasons for these weaknesses in the brand planning process come from:
 - Affiliate brand teams considering it is just a constraint, imposed by the regional or global teams, having little, if any, value for them
 - Insufficient time spent to carry out in-depth analyses to enhance market insights (knowledge and understanding)




The situation analysis should focus on identifying and analyzing current and future key market events from which implications for the brand will be deducted

Pitfall #1

Describing and not analyzing the market situation

What do we recommend?



- A robust analysis of the market situation requires to identify key market features, by gathering precise and reliable information regarding:
 - Sales data trends (historical and forecasted data)
 - Opinion and behavioral trends of key stakeholders (policy makers, payers, physicians, pharmacists¹, patients, patient advocacy groups (PAGs), pharma competitors)² who are likely to impact the market attractiveness and the competitive position
- Then, it is essential to understand the factors that drive stakeholders' opinion and behavior, and market attractiveness
- An in-depth market knowledge and understanding will enable to identify the major market opportunities and threats and to assess the brand strengths and weaknesses



The SWOT analysis is rarely properly structured, preventing from deducting the most relevant key strategic drivers to optimize the brand performance

Pitfall #2

Carrying out a sub-optimal SWOT analysis

What do we observe?

Conventional SWOT analytical tool

Market Opportunities

Market Threats	

Brand Strengths •

	Brand Weaknesses	
٠		

- The SWOT analysis constitutes a structured summary of the situation analysis from which the key strategic drivers (also called: key business drivers, key strategic imperatives, strategic priorities, etc.) should be drawn
- However, the conventional SWOT framework is not well conceived, leading to misuses:
 - It is frequent to see a long list of items, not always relevant, and considered to be of equal importance
 - Opportunities are often confused with strengths, and threats with weaknesses
 - It is not rare for an item to be mixed-up with its cause, leading to wrong strategic decisions¹
- The frequent inappropriate use of the SWOT framework has led detractors to rename it "Silly Way Of Thinking"

¹ For instance, the fact that a brand has a leading position on a therapeutic area is not necessarily a strength per se.

It may just be the result of a factor which is the strength, such as its superior efficacy, acceptability or convenience



The "Advanced SWOT" helps brand teams carry out a more specific and relevant assessment of the market situation and of the brand competitive position

Pitfall #2

Carrying out a sub-optimal SWOT analysis

What do we recommend?

Advanced SWOT analytical tool

Market Opportunities				
-	Authorities ²			
•	Customers ³			
•	Competitors			

	Market Threats	RI
-	Authorities	
•	Customers	
•	Competitors	

	Brand Strengths	RI
-	Product (4 Ps ⁴)	
•	Services	
•	Corporate reputation	

	Brand Weaknesses					
	Product (4 Ps)					
•	Services					
•	Corporate reputation					

- To facilitate the definition of the brand strategic drivers, it is recommended to use the "Advanced SWOT framework" which structures:
 - Market opportunities and threats into stakeholders' opinions and behaviors
 - Brand strengths and weaknesses into the product, the associated services and the reputation of the marketing company
- It is also essential to prioritize the items listed in each of the four components of the SWOT framework by evaluating their RI (relative importance) by using, for instance, a five-point scale
- These proposed adjustments of the SWOT framework have shown to be very helpful to transform it into a practical tool

Sources: Smart Pharma Consulting

¹ Relative Importance of each item, rated from 5, high importance to 1, low importance – ² Policy makers – ³ Payers, physicians, pharmacists, patients, patient advocacy groups – ⁴ Product features, price, distribution, promotion



The brand strategy is too often crafted irrespective of the market reality and is not structured so that to foster the synergy of the supporting activities across departments

Pitfall #3

Crafting an inconsistent strategy

What do we observe?

Strategic driver #1 Strategic driver #2 Strategic driver #3

- The strategic drivers, which are the priorities on which the company concentrates its resources and capabilities to achieve the performance objective set for its brand, should derive from the SWOT analysis
- The links between the situation analysis, summarized in a SWOT, and the selected strategic drivers, are not always clearly established and sometimes may even not exist
- In addition, if not properly put into perspective with the set objective, the selected strategic drivers may not be the most relevant ones and lead to a suboptimal brand performance
- When the activities corresponding to each strategic driver are not well-defined, across key different operational functions (i.e. market access, medical, marketing, sales), the quality of execution is in general poor



The Brand Strategy Card has shown to be a useful tool to align the brand ambition, the strategic drivers and the corresponding tactics

Pitfall #3

Crafting an inconsistent strategy

What do we recommend?



- The Brand Strategy Card shows the brand ambition, the strategic drivers selected to achieve that ambition and the key tactics to support the strategic drivers
- Thus, this one-page Brand Strategy Card helps to ensure the consistency between the three building blocks of the brand strategy: the ambition – the strategic drivers – the key tactics
- The trickiest part is to select the most relevant strategic drivers, as derived from the Advanced SWOT, which are...
- ... opportunities to seize, threats to fight again, strengths to capitalize on, and/or weaknesses to address
- The preferred strategic drivers are those which are the most likely to have an impact on the brand performance so that to achieve the set ambition for the brand



The tactics do not always support the strategic drivers and are too often limited to marketing and sales activities

Pitfall #4

Selecting tactics which do not support the strategy

What do we observe?

Table of key tactics

Tactic	Target	Timing	Responsible	Budget

- It is not rare to see, in brand plans, key tactics which do not formerly support the strategic drivers
- However, key tactics are the actions which are selected to support the strategy
- In other words, these actions are the operational expression of the strategic drivers
- Key tactics are too often described as a series of activities carried out by the marketing and sales departments...
- ... which are a renewal of past activities and for which objectives have not been clearly set and the impact formerly measured
- Being rarely based on the assessment of past experience, the process to prioritize these tactics is in general weak



Each tactic should be carefully selected to best support the strategic drivers to enhance the probability to achieve the brand ambition

Pitfall #4

Selecting tactics which do not support the strategy

What do we recommend?

Table of key tactics related to the strategic drivers

Strategic Dr	iver		Departme	epartment ¹		
Tactic	Target Objective		Timing	Responsible	Budget	

- Tactics should be carefully selected to best support each strategic driver
- These tactics may concern not only marketing and sales departments, but also market access and medical affairs departments
- If the medical affairs department is not supposed to promote brands, it can/should however contribute to optimize the use of the brands in the best interest of the patients, by generating and disseminating to healthcare professional relevant medical data
- It is important, for each tactic, to precise the target concerned, to set a precise objective, to plan it, to name a responsible and estimate a budget
- Before selecting a tactic, it may be needed to test the idea²

Sources: Smart Pharma Consulting

1 Market access, medical, marketing, sales, etc. – 2 By using a specific assessment tool as the one shown in our position paper

Excellence in Execution" p. 31 – https://smart-pharma.com/wp-content/uploads/2019/07/Smart-Management-Series-Excellence-in-Execution-VWF.pdf



It is rare to see brand plans with integrated monitoring tools and associated monitoring process, which therefore prevents from measuring the efficacy and efficiency of the selected tactics

Pitfall #5

Not integrating monitoring indicators

What do we observe?

Monitoring indicators

Tactic	Target	Objective	Timing	Responsible	Budget	KEIs ¹	KPIs ²
							ackslash
							$\overline{}$

- A brand plan without indicators to measure the quality of execution and the – direct or indirect – impact of the selected tactics on the business is of little use
- Rare are the companies which integrate, in their brand plan, indicators to measure the quality of execution (Key Execution Indicators) and/or the impact (Key Performance Indicators) of tactics
- Without these indicators and the implementation of a monitoring process, it is impossible to evaluate the efficacy and efficiency of the tactics planned in the brand plan
- Thus, a brand plan with no systematic monitoring can be viewed as a window-dressing exercise

"If you can't measure it, you can't manage it!" – Peter Drucker



KEIs¹ and KPIs² are both essential, the first type of indicators measuring the quality of execution and the second one the degree of objective achievement

Pitfall #5

Not integrating monitoring indicators

What do we recommend?



Monitoring indicators



Quantitative

- % of customer target covered
- Number of interactions with customers
- Number of projects carried out
- Level of resources allocated to customers
- Number of new customers
- Average # of prescriptions per customer
- Sales dynamics
- Return on investment

Qualitative

- Quality of interactions with customers
- Level of market insights
- Proper management of projects, from the customer perspective
- Brand Preference Mix Index
- Corporate reputation improvement
- Perceived quality of products
- Perceived value of services

- All brand plans should include monitoring tools and a monitoring process related to each selected tactic
- We recommend to use:
 - Key Execution Indicators (KEIs) which measure the quality of execution of tactics
 - Key Performance Indicators (KPIs) which measure the business outcome of tactics
- By measuring carefully, the quality of execution and the impact of tactics, it is possible to adjust the brand plans (during the year or from the previous year) to make them more efficient and effective

"KEIs check that you are on the right track and KPIs check that you arrive at destination"



3. Key takeaways

"High-Performance Pharma Brand Plans require method, rigor and pragmatism"

Recommendations

- Design brand plans with the intent of helping allocating the right resources to achieve brand performance ambition, and not just as a formality to be reported at corporate level
- Adopt the 4Ws¹ (What? Why? so What? What to do?) approach to improve the relevance, the consistency and the robustness of the brand plans
- Use the "Advanced SWOT" to facilitate the analysis of the market situation and of the brand competitive position, identifying market opportunities and threats and prioritizing brand strengths and weaknesses

- Seek customer preference rather than customer satisfaction by improving customers perception of the brand attributes, the quality of the proposed services and the corporate reputation
- Make the best use of the "Brand Strategy Card" to formalize clearly and precisely the brand ambition, the strategic drivers and the corresponding key tactics
- Define Key Execution Indicators and Key Performance Indicators to monitor respectively the quality of execution and the impact of tactics

1 What: gathering of data regarding market sales and stakeholders' opinion and behavior. Why: understanding of the factors triggering market and stakeholders' data. So What: implications for the brand. What to do: strategic and tactical decisions to be made to achieve the brand ambition, based on the situation analysis



4. Smart Pharma Service Offering

Consulting Services

- Smart Pharma Consulting is well-known for its ability to help brand teams build robust brand plans
- To date, Smart Pharma consultants have helped 35 pharma companies develop strategic and tactical plans on more than 80 brands belonging to 18 different therapeutic areas
- Thus, we can bring our support to address the following issues:
 - Which market analyses should be carried out?
 - How to define market key success factors and the corresponding brand challenges with the help of the "Advanced SWOT"?
 - How to develop market and brand scenarios?
 - How to define the brand performance ambition?
 - How to craft a specific strategy to achieve the brand ambition?
 - How to support the strategy by tactical initiatives likely to reinforce the preference of stakeholders for the brand?
 - How to anticipate the impact of future investment options on the brand performance?
 - How to monitor the quality of execution and the impact of investment decisions?

Training Program

	Example of a One-Day Program ¹
8:30	Introduction to the program
8:40	Definitions, concepts, methods, tools related to Brand Plans
9:00	Module 1: Situation analysis Market definition and dynamics Stakeholders' opinion and behavioral analysis
10:30	Break
10:50	Advanced SWOT analysis
12:00	Module 2: Sales forecasting & ambition setting
13:00	Lunch
14:00	Module 3: Strategy crafting
15:00	Module 4: Tactics selection
16:00	Break
16:20	Module 4: Tactics monitoring
17:30	Conclusion and key takeaways
18:00	End of the program
	Target Audience

 Collaborators involved in supporting the brands (e.g. from the medical, marketing, commercial, market research, strategic,... departments), whatever their level of responsibility and seniority

Sources: Smart Pharma Consulting ¹ The program content can be customized



Consulting firm dedicated to the pharmaceutical sector operating in the complementary domains of strategy, management and organization

The Smart Tool Series

- This series intends to provide practical tools and recommendations to enhance the efficacy and efficiency of the most important activities or processes in place within pharma companies
- Our tools and recommendations are based on both:
 - Our consulting experience in the pharma sector
 - Our research for innovative, pragmatic and useful solutions
- Each issue of this new series has been designed to be read in 15 to 20 minutes and not to exceed 20 pages

High-Performance Pharma Brand Plans

The 5 Pitfalls to avoid

- Brand Plans are often inefficient and of little use due to a weak building process, a lack of market insight and an insufficient involvement of brand teams
- We have identified 5 pitfalls and recommended solutions to address them to create High-Performance Pharma Brand Plans, enabling to boost effectively and efficiently brand performance

Smart Pharma Consulting Editions



- Besides our consulting activities which take 85% of our time, we are strongly engaged in sharing our knowledge and thoughts through:
 - Our teaching activities in advanced masters (ESSEC B-school, Paris Faculty of Pharmacy)
 - Training activities for pharma executives
 - The publication of articles, booklets, books and expert reports
- Our publications can be downloaded from our <u>website</u>:
 - 41 articles
 - 77 position papers covering the following topics:
 - Market Insights
- Marketing

2. Strategy

- 6. Sales Force Effectiveness
- 3. Market Access
- 7. Management & Trainings
- 4. Medical Affairs
- Our research activities in pharma business management and our consulting activities have shown to be highly synergistic
- We remain at your disposal to carry out consulting projects or training seminars to help you improve your operations

Best regards

Jean-Michel Peny